Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice

Jonathan D. Schertzer, James G. Ryall, and Gordon S. Lynch

Basic and Clinical Myology Laboratory, Department of Physiology, The University of Melbourne, Victoria, Australia

Submitted 10 April 2006; accepted in final form 12 April 2006


The absence of dystrophin and resultant disruption of the dystrophin glycoprotein complex renders skeletal muscles of dystrophic patients and dystrophic mdx mice susceptible to contraction-induced injury. Strategies to reduce contraction-induced injury are of critical importance, because this mode of damage contributes to the etiology of myofiber breakdown in the dystrophic pathology. Transgenic overexpression of insulin-like growth factor-I (IGF-I) causes myofiber hypertrophy, increases force production, and can improve the dystrophic pathology in mdx mice. In contrast, the predominant effect of continuous exogenous administration of IGF-I to mdx mice at a low dose (1.0–1.5 mg·kg⁻¹·day⁻¹) is a shift in muscle phenotype from fast glycolytic toward a more oxidative, fatigue-resistant, slow muscle without alterations in myofiber cross-sectional area, muscle mass, or maximum force-producing capacity. We found that exogenous administration of IGF-I to mdx mice increased myofiber succinate dehydrogenase activity, shifted the overall myosin heavy chain isoform composition toward a slower phenotype, and, most importantly, reduced contraction-induced damage in tibialis anterior muscles. The deficit in force-producing capacity after two damaging lengthening contractions was reduced significantly in tibialis anterior muscles of IGF-I-treated (53 ± 4%) compared with untreated mdx mice (70 ± 5%, P < 0.05). The results provide further evidence that IGF-I administration can enhance the functional properties of dystrophic skeletal muscle and, compared with results in transgenic mice or virus-mediated overexpression, highlight the disparities in different models of endocrine factor delivery.

insulin-like growth factor-I; fiber type; myosin heavy chain; muscular dystrophy

ABSENCE OF THE CYTOSKELETAL PROTEIN DYSTROPHIN IN DUCHENNE MUSCULAR DYSTrophy (DMD) disrupts the dystrophin glycoprotein complex (DGC), a cluster of proteins spanning the sarcolemma that are important in providing cytoskeletal support and regulating intracellular signaling (27, 40). The mdx mouse, a widely used animal model of DMD, also harbors a mutation in the dystrophin gene and lacks functional levels of dystrophin protein. Although mdx mice exhibit a more benign phenotype compared with DMD patients, the compromised structural integrity of dystrophin-deficient skeletal muscle renders it highly susceptible to contraction-mediated injury (5, 9, 20, 22). In general, contraction-induced damage occurs when activated muscles are subjected to forced lengthening. The susceptibility to contraction-induced damage in dystrophic muscle may be attributed to an aberration in the link between the cytoskeleton

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
nervation (32), and various myopathies including muscular dystrophy (3, 33).

Undoubtedly, gene manipulation will eventually have tremendous implications for muscular dystrophy and other muscle diseases. However, several obstacles such as vector design, the possibility of insertional mutagenesis, and achieving systemic delivery to therapeutic levels must be overcome for these methodologies to reach widespread clinical use (31). As such, there is an immediate need for clinically relevant treatment strategies for muscular dystrophies.

Previous studies have demonstrated that slow-twitch muscles from mdx mice are less susceptible to contraction-induced damage than fast-twitch muscles (7). On the basis of these findings, and the fact that continuous low-dose exogenous IGF-I administration increases the oxidative capacity of skeletal muscles (10), we hypothesized that a similar regimen could reduce contraction-induced damage in mdx mice, in part by inducing a shift in overall muscle phenotype toward more slow muscle characteristics.

MATERIALS AND METHODS

Experimental design. All procedures were approved by the Animal Experimentation Ethics Committee of The University of Melbourne and conformed to the Guidelines for the Care and Use of Experimental Animals described by the National Health and Medical Research Council (Australia). Male C57BL/10ScSnmdx/J (dystrophic) mdx mice (20–23 wk of age) were randomly assigned to either untreated or IGF-I-treated groups (with at least 7 mice per group). Treated mice received recombinant human IGF-I (GroPep, Thebarton, South Australia) exogenously at a dose of ~1.5 mg/kg body mass daily for a period of 8 wk via miniosmotic pump, as described previously (10, 11). Investigators in our laboratory have shown previously that systemic administration of IGF-I by miniosmotic pump increases IGF-I levels in the blood (10, 11), rather than increasing muscle IGF-I levels, as in transgenic mice (3). For some experiments, age-matched C57BL/10ScSn mice were used as wild-type controls (n = 3). Some histological assessments of myofiber membrane permeability also required some mice (n = 3 per group) to be injected intraperitoneally with 10 μL/g body wt Evans’s blue dye (EBD; 1% vol/vol) 20 h before experimentation, as our group has described previously (28).

Skeletal muscle contractile properties measured in situ. Contractile properties of TA muscle were measured in situ as described previously (28). Mice were anesthetized with pentobarbital sodium (Nembutal; Rhone Merieux, Pinkenba, Queensland, Australia; 60 mg/kg ip), and the right TA muscle was exposed by a single incision. The tendon of the TA was cut several millimeters distal to the end of the muscle and tied securely to the lever arm of a dual-mode servomotor (model 305B-LR; Aurora Scientific, Richmond Hill, Ontario, Canada). The foot of the mouse was immobilized by clamping it to the platform, and a pin was passed behind the patellar tendon to immobilize the knee. The TA muscle was stimulated by supramaximal (10 V) 0.2-ms square-wave pulses for 300 ms in duration, delivered via two wire electrodes adjacent to the femoral nerve. Optimum muscle length (L0) was determined from Pt and Po, recorded from the plateau of full frequency-force curve. Optimum fiber length (Ls) was determined by multiplying L0 by the TA L0/Ls ratio of 0.6 (6). The contraction-induced injury protocol used in this study was similar to that described previously (9). To avoid muscle fatigue, we performed only two lengthening contractions, each separated by a 10-s rest period. An isometric contraction was initiated and held for 100 ms to allow a plateau in maximal force. Muscle lengthening (30% L0) at a velocity of 2 Ls/s was initiated from the plateau of the isometric contraction, and stimulation was terminated at the end of the stretch. Maximum isometric force was determined 5 min after the lengthening contractions. The “force deficit” after contraction-induced damage was determined by calculating the difference between the Po measured 5 min after the lengthening contractions and the Po determined before lengthening contractions and was expressed as a percentage of maximum Po determined before lengthening contractions (9).

Histology and immunofluorescence. TA muscles were surgically excised, weighed on an analytical balance, mounted in embedding medium, frozen in thawing isopentane, and then stored at −80°C. A portion of each frozen muscle sample was cryosectioned transversely (8 μm) through the mid-belly region. Muscle sections used for EBD analysis were incubated for 5 min in methanol at −20°C and air-dried at room temperature, and EBD-positive fibers were identified using fluorescent microscopy with a wide-band interference green (WIG) filter (excitation 520–550 nm; emission 565 ± nm), as described previously (28). Muscle sections were stained with hematoxylin and eosin to determine general muscle architecture, the percentage of fibers with centrally located nuclei, and the cross-sectional area (CSA) of individual myofibers. Muscle sections were reacted for SDH activity and analyzed as described previously (11, 12, 26). Median values for CSA and SDH activity were calculated from at least 300 individual muscle fibers per sample. Mice were killed by cardiac excision, and heart, liver, EDL, and soleus muscles were recorded. Tibial length was determined using digital calipers and was measured from the knee to ankle joint along the longitudinal axis of the left tibia.

Myosin heavy chain isoform analysis by SDS-PAGE and RT-PCR. Muscles (n = 3 per group) were homogenized, and myosin heavy chain (MHC) proteins were separated by SDS-PAGE as described previously (13, 29, 36). Because the TA muscle is composed of predominantly fast-twitch fibers, only MHC Ila/x and MHC Iib isoforms could be detected reliably by SDS-PAGE, although transcripts could be detected for the other MHC isoforms. A small portion (~25 μg) of the TA muscle (n = 3 per group) was mechanically homogenized with a Polytron homogenizer and used for RNA extraction and analysis as described previously (13). Total RNA from TA muscle was isolated using a commercially available kit (no. 74704; Qiagen, Valencia, CA). RNA concentration was determined as UV absorption at 260 nm, and the samples were stored at −80°C. Semiquantitative RT-PCR was performed on 100 ng of total RNA. RT and PCR were performed using a commercially available kit (no. 74704, Qiagen). A standard RT-PCR protocol was used and consisted of 30 min at 50°C, 15 min at 95°C, and repeated cycles of denaturation (94°C, 45 s), annealing (various temperatures, 45 s), and extension (72°C, 45 s). The forward primer used for all MHCs (except for embryonic MHC) was 5'-GAAGGGCCAAAGAGGCATCC-3'. The reverse primers used for specific MHC isoforms were MHC Ila, 5'-TCTACAGCAGCAGCTGCCCC-3'; MHC IIX, 5'-GGTCATTGTGCTGTTGGAA-3'; and MHC Iib, 5'-GTGTCATGCTGTTGCTGACC-3'. The forward and reverse primers for embryonic MHC were 5'-GAAGGGCCAAAGGCCATCA-3' and 5'-CCCTACCAAGAGGACATGC-3', respectively. The RT-PCR

Table 1. Morphological properties of dystrophic mdx mice after 8 wk of continuous IGF-I administration via miniosmotic pump

<table>
<thead>
<tr>
<th>Body Mass, g</th>
<th>Control mdx</th>
<th>IGF-I mdx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart mass, mg</td>
<td>145.1 ± 5</td>
<td>145.9 ± 4</td>
</tr>
<tr>
<td>Liver mass, g</td>
<td>1.6 ± 1</td>
<td>1.6 ± 1</td>
</tr>
<tr>
<td>EDL mass, mg</td>
<td>17.9 ± 1</td>
<td>17.7 ± 1</td>
</tr>
<tr>
<td>Soleus mass, mg</td>
<td>12.5 ± 1</td>
<td>13.0 ± 1</td>
</tr>
<tr>
<td>TA mass, mg</td>
<td>108.0 ± 5</td>
<td>108.9 ± 3</td>
</tr>
</tbody>
</table>

Values are means ± SE. Insulin-like growth factor-I (IGF-I) was administered at ~1.5 mg·kg−1·day−1, EDL, extensor digitorum longus; TA, tibialis anterior.
PRODUCTS WERE ELECTROPHORESED ON 2% AGAROSE GELS IN TRIS-ACETATE-EDTA BUFFER AND PHOTOGRAPHED UNDER UV LIGHT AFTER STAINING WITH ETHIDIUM BROMIDE. BY TITRATING THE NUMBER OF CYCLES FOR EACH GENESPECIFIC PRIMER PAIR, IT WAS PROVEN THAT THE AMPLIFIED SIGNAL WAS ON THE LINEAR PORTION OF A SEMILOGARITHMIC PLOT OF THE YIELD, EXPRESSED AS A FUNCTION OF THE NUMBER OF CYCLES.

STATISTICAL ANALYSIS. INDIVIDUAL VARIABLES WERE COMPARED BETWEEN GROUPS WITH AN UNPAIRED t-TEST OR ONE-WAY ANALYSIS OF VARIANCE (ANOVA) AS APPROPRIATE. BONFERRONI’S POST HOC MULTIPLE COMPARISON PROCEDURE WAS USED TO DETECT DIFFERENCES BETWEEN SPECIFIC MEANS. SIGNIFICANCE WAS SET AT P < 0.05. BECAUSE SDH ACTIVITY AND MUSCLE FIBER CSA DATA WERE NOT NORMALLY DISTRIBUTED, 95% CONFIDENCE INTERVALS (CI) OF THE MEDIAN WERE USED FOR ASSESSING DIFFERENCES BETWEEN GROUPS. ALL OTHER VALUES ARE EXPRESSED AS MEANS ± SE, UNLESS SPECIFIED OTHERWISE.

RESULTS

SKELETAL MUSCLE MÖRPHOMETRIC AND CONTRACTILE PROPERTIES. CONTINUOUS ADMINISTRATION OF IGF-I PROTEIN FOR 8 WK DID NOT ALTER MORPHOMETRIC PROPERTIES SUCH AS BODY MASS, HEART MASS, LIVER MASS, EDL MASS, SOLEUS MASS, TA MASS, AND TIBIAL LENGTH (TABLE 1). SIMILARLY, IGF-I ADMINISTRATION DID NOT ALTER THE MAJORITY OF CONTRACTILE PROPERTIES OF THE TA MEASURED IN SITU. IGF-I ADMINISTRATION DID NOT ALTER P0, THE RATE OF FORCE DEVELOPMENT OF THE TWITCH, THE TIME REQUIRED TO REACH PEAK TENSION, MAXIMUM TETANIC FORCE (P0), OR MAXIMUM TETANIC FORCE NORMALIZED FOR OVERALL MUSCLE CSA (SPECIFIC FORCE; SP0; TABLE 2). HOWEVER, IGF-I ADMINISTRATION PROLONGED ONE-HALF RELAXATION TIME OF THE ISOMETRIC TWITCH BY 11% (P < 0.05; TABLE 2).

Table 2. Contractile properties of TA muscles from dystrophic mdx mice after 8 wk of continuous IGF-I administration via miniosmotic pump

<table>
<thead>
<tr>
<th></th>
<th>Control mdx</th>
<th>IGF-I mdx</th>
</tr>
</thead>
<tbody>
<tr>
<td>P0, mN</td>
<td>683.3±31</td>
<td>649.9±53</td>
</tr>
<tr>
<td>dP/dt, mN/ms</td>
<td>96.0±4</td>
<td>90.7±4</td>
</tr>
<tr>
<td>TPT</td>
<td>15.9±1</td>
<td>16.6±1</td>
</tr>
<tr>
<td>1/2RT</td>
<td>13.3±1</td>
<td>14.7±1*</td>
</tr>
<tr>
<td>P0, mN</td>
<td>2,204.4±87</td>
<td>2,065.1±91</td>
</tr>
<tr>
<td>sP0, kN/m2</td>
<td>198.3±5</td>
<td>186.7±7</td>
</tr>
<tr>
<td>1st lengthening contraction, mN</td>
<td>4,117.1±296</td>
<td>4,536.6±212</td>
</tr>
<tr>
<td>2nd lengthening contraction, mN</td>
<td>3,397.1±203</td>
<td>3,927.2±231</td>
</tr>
<tr>
<td>Maximum force after damage, mN</td>
<td>631.9±61</td>
<td>957.9±34*</td>
</tr>
<tr>
<td>Force deficit, %</td>
<td>70.7±5</td>
<td>53.0±4*</td>
</tr>
</tbody>
</table>

Values are means ± SE. *IGF-I was administered at ~ 1.5 mg/kg day−1. P0, maximal twitch force; dP/dt, maximal rate of force development during twitch response; sP0, specific force (maximum tetanic force/muscle cross-sectional area); TPT, time to peak twitch tension; 1/2RT, twitch half-relaxation time; P0, maximum tetanic force production. Force deficit was determined by calculating the difference between the P0 before and after lengthening contractions and is expressed as a percentage of maximum P0, determined before the lengthening contractions.

The percentage of EBD-positive fibers was slightly higher after contractions and is expressed as a percentage of maximum P0, determined before the lengthening contractions.

SUSCEPTIBILITY TO CONTRACTION-INDUCED DAMAGE. ONE OF THE MAJOR FINDINGS OF THIS STUDY WAS THAT IGF-I ADMINISTRATION REDUCED THE FORCE DEFICIT OF TA MUSCLES FROM mdx MICE AFTER THE CONTRACTION-INDUCED INJURY PROTOCOL. SPECIFICALLY, 5 min after two lengthening contractions, P0 was 957.9 ± 34 mN in IGF-I-treated mdx mice and 631.9 ± 61 mN in untreated mdx mice. This corresponded to a significantly lower force deficit of 53 ± 4% compared with 70.7 ± 5% in treated and untreated groups, respectively (P < 0.05; Table 2; Fig. 1). Importantly, IGF-I administration did not affect the force production during lengthening contractions (Table 2; Fig. 1). Functional measurements of TA muscles of age-matched male C57BL/10 wild-type mice (n = 3) demonstrated significantly lower values for P0 (1,760.2 ± 82 mN; P < 0.05), higher values for sP0 (291.0 ± 11 kN/m2; P < 0.05), and lower force deficits 5 min after two lengthening contractions (17.9 ± 1%; P < 0.05) compared with mdx mice (data not shown).

HISTOLOGY AND IMMUNOFLORESCENCE. Median and individual values for TA muscle fiber CSA are presented in Fig. 2. The median CSA was not different in TA muscles of untreated mdx mice (2,844 – 3,001 μm²; 95% CI of median; n = 1,951 fibers) compared with mdx mice administered IGF-I for 8 wk (2,738 – 2,899 μm²; 95% CI of median; n = 1,950 fibers). Similarly, the percentage of centrally nucleated fibers identified in transverse sections of TA muscles was not different in mdx mice (87 ± 2%) compared with IGF-I-treated mdx mice (84 ± 1%; Fig. 2).

The percentage of EBD-positive fibers in transverse sections of TA muscles was not different in untreated mdx mice (10 ± 4%) compared with IGF-I-treated mdx mice (8 ± 4%; Fig. 3). The percentage of EBD-positive fibers was slightly higher after contraction-induced damage in TA muscles of mdx mice (main...
Median and individual values for SDH activity in TA muscle fibers are presented in Fig. 4. The median SDH activity was significantly higher in TA muscles of mdx mice after continuous IGF-I administration (6.00–6.14 mM/min; 95% CI of median; n = 2,205 fibers) compared with TA muscles of untreated mdx mice (5.64–5.76 mM/min; 95% CI of median; n = 2,204 fibers).

**MHC isoform analysis by SDS-PAGE and RT-PCR.** MHC IIa/x and MHC IIb protein isoforms could be detected in TA muscles of mdx mice by SDS-PAGE (Fig. 5A). TA muscles from untreated mdx mice contained 22.9 ± 3% MHC IIa/x and 77.1 ± 3% MHC IIb. IGF-I treatment significantly altered the MHC protein isoform profile such that TA muscles contained a higher percentage of MHC IIa/x (35 ± 4%) and a lower percentage of MHC IIb (65 ± 4%; P < 0.05; Fig. 5A).

Semiquantitative RT-PCR of total RNA with gene-specific primers demonstrated that IGF-I administration increased MHC IIa transcript by 244 ± 44% and MHC IIx by 248 ± 45% compared with untreated TA muscles of mdx mice (P < 0.05; Fig. 5). IGF-I administration did not alter mRNA levels

---

**Fig. 2.** A: hematoxylin- and eosin-stained transverse sections of uninjured TA muscle sections before (uninjured) or after contraction-induced damage (stretch) in C57BL/10 mice (BL/10), untreated mdx mice (mdx CON), and mdx mice administered IGF-I for 8 wk (mdx IGF-I). B: individual and median data for myofiber cross-sectional area (CSA).

**Fig. 3.** Evan’s blue dye in uninjured transverse TA muscle sections before (uninjured) or after contraction-induced damage (stretch) in BL/10, mdx CON, and mdx IGF-I mice.

---

effect; P < 0.05), but IGF-I administration had no effect on EBD infiltration, because the percentage of EBD-positive fibers was not different in mdx mice (16 ± 5%) compared with IGF-I-treated mdx mice (17 ± 5%; Fig. 3). EBD-positive fibers could not be detected in TA muscles of C57BL/10 wild-type mice (n = 3) in control or contraction-induced damage groups (Fig. 3).
of MHC IIb but reduced mRNA levels of embryonic MHC isoform to 52 ± 20% of untreated TA muscles of mdx mice (P < 0.05; Fig. 5B). These results indicate that the shift in MHC isoform profile toward a slower phenotype induced by continuous low-dose IGF-I administration is regulated at the level of transcription. It also is clear that the TA muscles of mdx mice contain predominantly MHC IIb and MHC IIx isoforms, because they were the only protein isoforms reliably detected by SDS PAGE and analysis of mRNA isoforms required only 18 cycles of PCR amplification compared with 30 and 35 cycles of amplification for MHC IIa and embryonic MHC, respectively (Fig. 5B).

**DISCUSSION**

The most important finding of this study was that continuous IGF-I administration at a relatively low dose (1.5 mg·kg⁻¹·day⁻¹) for 8 wk significantly reduced contraction-induced damage in TA muscles of mdx mice, providing further support for the notion that IGF-I administration can enhance the functional properties of dystrophic skeletal muscle. This is pertinent because skeletal muscles lacking dystrophin are highly susceptible to contraction-mediated damage, and this mode of injury contributes to the etiology of the dystrophic pathology. As such, studies on contraction-based damage assays and modalities to prevent or reduce this mode of injury in dystrophic muscle are needed (16).

The findings provide further evidence that the predominant effect of exogenous low-dose IGF-I administration in mice is a shift toward a slow muscle phenotype (10, 11). We found an increased median SDH activity and altered MHC composition in the TA muscles of mdx mice after IGF-I administration. In agreement with our previous studies, we found that IGF-I treatment shifted the MHC isoform profile from MHC IIb to MHC IIa/x in TA muscles of mdx mice (11). This effect was regulated at the transcription level, because IGF-I administration caused an increase in the mRNA levels of MHC IIa and MHC IIx, whereas MHC IIb was unchanged. The net effect of these changes was consistent with a small but significant shift from a fast to an overall slower phenotype. Interestingly, IGF-I administration decreased transcript levels of the embryonic MHC isoform. The link between this effect and muscle regeneration, muscle function, or the susceptibility to contraction-induced damage has yet to be identified.

We found that the reduction in susceptibility to contraction-induced damage after IGF-I administration was not linked to changes in EBD uptake. Previous studies have demonstrated that a single lengthening contraction (of a similar magnitude to that used in this study) did not result in a significant increase in procion orange uptake in myofibers of EDL or soleus muscles of mdx mice (7), whereas a series of five lengthening contractions significantly increased procion orange uptake in the diaphragm of mdx mice (22). Thus it appears that the extent of membrane damage is dependent on the number of lengthening contractions and/or the muscle tested. We found that as few as two lengthening contractions resulted in small but significant membrane damage in TA muscles of mdx mice, an effect not
seen in muscles from C57BL/10 mice. However, based on the force deficit in TA muscles of mdx mice after this injury protocol, membrane damage seems to play only a minor role (if any) in the lengthening contraction-mediated decrease in maximum force production, suggesting that IGF-I did not confer its protective effect via an increase in membrane stability. It also is possible that IGF-I administration could have improved force production in a subset of muscle fibers after contraction-induced damage.

Models of high-level IGF-I overexpression (e.g., transgenic mice) have indicated clearly that IGF-I can cause skeletal muscle hypertrophy and increase force generation in mdx mice (3). A recent study demonstrated that virus-mediated IGF-I overexpression in 9-mo-old mdx mice did not increase maximum force production of TA muscles and had less obvious effects on muscle morphology compared with transgenic approaches (1). On the basis of the ability of IGF-I to ameliorate the initial wave of myonecrosis in mdx mice (33), it has been suggested that transgenic overexpression before the onset of the initial phase of degeneration in mdx mice is critical for its beneficial effects (1). Virus-mediated IGF-I overexpression was found not to protect TA muscles from contraction-induced damage induced by a single lengthening contraction (1). As such, differences in the dose of IGF-I with the use of virus-mediated overexpression compared with the relatively low dose of IGF-I administered exogenously in the present study may be critical for its differential effects on dystrophic skeletal muscles.

A relatively low dose of IGF-I administration did not cause myofiber hypertrophy in mdx mice in this or previous studies (10, 11), but a similar regimen of exogenous IGF-I administration caused myofiber hypertrophy and increased force production in laminin-deficient dystrophic 129 Re/Jbyid mice (17). Hence, discrepancies regarding the effects of IGF-I on muscle hypertrophy, oxidative potential, and phenotype may be due to the dose and timing of IGF-I employed and the experimental animal model used to test its effects. Further research is required to discern the intracellular signaling cascades that may be responsible for these differences.

Assessment at the cellular (single fiber) level has shown that rat slow-twitch muscle fibers are less susceptible to contraction-induced injury than fast-twitch fibers, at a given percentage of strain beyond optimum length (19). In addition, slow-twitch muscle fibers required a greater strain beyond optimum length to achieve the same force deficit as fast-twitch fibers (19). One study has reported that fast and slow muscles of laminin-deficient dystrophic mice were not more susceptible to lengthening contractions compared with muscles from control mice (14). However, that study showed that fast (but not slow) muscles of dystrophic and control mice were susceptible to contraction-induced damage. Similar studies have not been performed to compare fast- and slow-twitch fibers from muscles of dystrophin-deficient mdx mice. An inviting hypothesis is that dystrophic muscle fibers composed of MHC IIB are more susceptible to contraction-induced injury than fibers composed predominantly of MHC I or IIa/x. It has been suggested that the difference in fiber susceptibility to contraction-mediated injury is dependent on chronic activity patterns, rather than fiber type composition (37). It is highly unlikely that exogenous IGF-I administration altered the chronic activation patterns of TA muscles in the current study. It is noteworthy that the assessment of contraction-induced damage in dystrophic muscle used in the present study is dramatically different from that of other studies which concluded that oxidative capacity does not protect muscle fibers from eccentric contraction-induced damage, such as, for example, one study that employed up to 900 cyclic lengthening contractions over a 30-min period (21), a protocol that would void any physiological differences between muscles of dystrophic and wild-type mice.

In addition to alterations in MHC isoform composition, our working hypotheses to explain the reduction in contraction-induced damage after IGF-I treatment in dystrophic muscle include alterations in components of excitation-contraction coupling (24) in the absence of myofiber hypertrophy and/or changes in titin isoforms (15), which may be associated (but not caused) by changes in MHC isoforms. Support for this hypothesis comes from the findings of Renganathan et al. (24), who showed that transgenic mice that overexpressed IGF-I had a significant (52%) increase in the number of dihydropyridine receptors (DHPR) in EDL muscle. Thus, given that excitation-contraction uncoupling has been proposed as a contributing mechanism to the force deficit following contraction-mediated damage (23, 38), an increase in the number of DHPR may attenuate disrupted excitation-contraction coupling. Although this is speculative, similar mechanisms may account for the effects of IGF-I on the force deficit immediately following contraction-induced damage. It has been proposed that different titin isoforms in fast and slow muscles may contribute to the differential susceptibility to contraction-induced injury (15, 19).

In summary, exogenous administration of IGF-I at a relatively low dose was associated with a reduced susceptibility of dystrophic muscles to contraction-induced injury. The predominant effect of this treatment protocol to mdx mice was to induce a shift toward a more oxidative, fatigueresistant, slow-twitch muscle phenotype in the absence of changes to myofiber CSA, muscle mass, or maximum force-producing capacity (10). Our results, when compared with other models of IGF-I overexpression, highlight the disparities between different modes of endocrine factor delivery. IGF-I has many effects on skeletal muscle, and these may differ depending on the age of the host, the IGF-I isoform used (2), and the dose and/or route of IGF-I administration. Discerning these effects and the underlying signaling events responsible for these differences is important for the development of successful treatments for skeletal muscle wasting disorders, especially myopathies.

ACKNOWLEDGMENTS

We acknowledge the technical assistance of Cleo Labiris for some aspects of the histological analysis.

GRANTS

This work was supported by research grants from the Muscular Dystrophy Association (USA) and the National Health and Medical Research Council (Australia).

REFERENCES


E505


